Journal of Blood Disorders & Transfusion

Xia Bai

Publications

• Research Article
  Efficiency of Intensive Immune -Suppression Treatment with Rituximab in Acquired Thrombotic Thrombocytopenic Purpura: A Chinese Case study
  Author(s): Fang Hu, Ziqiang Yu, Jian Su, Ling Sun, Tianqin Wu, Zhaoyue Wang, Xia Bai and Changgeng RuanFang Hu, Ziqiang Yu, Jian Su, Ling Sun, Tianqin Wu, Zhaoyue Wang, Xia Bai and Changgeng Ruan
  
  Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and functional failure of the organs due to ADAMTS13 deficiency. ADAMTS13 inhibitor is the main contributor of pathogenesis in acquired TTP. With the help of retrospective analysis the researchers tried to evaluate the effectiveness of rituximab in preventing the acquired TTP in China. Out of 27 patients with acquired TTP that have registered from 2006 to 2015, eleven cases started rituximab infusion before remission, while sixteen others began rituximab infusion after remission. Twenty-three cases got rituximab with standard doses (375 mg/m2 , weekly for 4 weeks) and four patients were administered reduced doses (100mg, weekly for 4 weeks) after remission. Till date, there was no patient reported with the acquired TTP relapsed during the.. View More»
  DOI: 10.4172/2155-9864.1000290

  Abstract PDF